Biblio
Altered Oxidative Phosphorylation Confers Vulnerability on IDH1-Mutant Leukemia Cells: Is This Therapeutically Tractable?. Blood Cancer Discov. 2024:OF1-OF3.
. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS). Blood Rev. 2023:101128.
Clinical outcomes and evolution of clonal hematopoiesis in patients with newly diagnosed multiple myeloma. Cancer Res Commun. 2023.
Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2021.
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes. J Clin Oncol. 2021:JCO2002810.
Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4(16):4029-4044.
. Clonal Hematopoiesis as a Model for Premalignant Changes During Aging. Exp Hematol. 2019.
. Allogeneic stem cell transplantation in myelodysplastic syndromes: does pretransplant clonal burden matter?. Curr Opin Hematol. 2015.
. Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc. 2015;90(7):969-83.
.